Form 4: Leap Therapeutics Executive Granted Stock Options

John Mark O'Mahony, Chief Manufacturing Officer of Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024.

Summary

• John Mark O'Mahony, the Chief Manufacturing Officer of Leap Therapeutics, Inc., was granted employee stock options on October 2, 2024.
• The options are for 85,000 shares of common stock at an exercise price of $2.45.
• The options vest in 36 equal monthly installments, starting one month after the grant date, contingent upon continued employment with the company.
• Following the transaction, O'Mahony directly owns 85,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. It reflects a standard executive compensation practice, indicating confidence in the company's future performance and the executive's role in it.

Positives

• The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing performance and company growth.
• The vesting schedule encourages long-term commitment from the Chief Manufacturing Officer.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to attract and retain key personnel, aligning their interests with the long-term success of the company. This is a standard incentive package for executives.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead, and Biogen routinely use stock options to incentivize their executives.
• The vesting schedule of 36 months is also standard practice, aligning with industry norms for long-term retention.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes management to increase shareholder value.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates